Friday, 16 October 2026European Markets

SPBK1 RINGERIKE And CRCAM TOURAINE CCI Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - spbk1 ringerike (ring.ol) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
spbk1 ringerike (ring.ol) kr316.00 4.17% 10.56%
crcam touraine cci (crto.pa) €81.52 3.89% 3.77%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. spbk1 ringerike (ring.ol)

4.17% forward dividend yield and 10.56% return on equity

sparebank 1 ringerike hadeland provides various banking products and services to private and corporate customers in norway. the company offers saving, current, deposit, and currency accounts; vehicle, house and travel, and animal insurance products, as well as life, child, disability, critical illness, accident, health, and business and personal insurance products; mobile and online banking services; and debit and credit cards. it also provides mortgages; car, boat, and other vehicles; consumer and other loans; and bank guarantees, corporate and construction loans, liquidity loans with a government guarantee, and operating credit for agriculture, as well as factoring, leasing, and overdraft services. in addition, the company offers services for buying and selling property; accounting services; pension products; and savings and investment products. the company was founded in 1833 and is based in hønefoss, norway.

earnings per share

as for profitability, spbk1 ringerike has a trailing twelve months eps of kr26.65.

pe ratio

spbk1 ringerike has a trailing twelve months price to earnings ratio of 11.86. meaning, the purchaser of the share is investing kr11.86 for every norwegian krone of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.56%.

more news about spbk1 ringerike.

2. crcam touraine cci (crto.pa)

3.89% forward dividend yield and 3.77% return on equity

caisse régionale de crédit agricole mutuel de la touraine et du poitou société coopérative provides various banking products and services in france. it offers bank accounts and cards, savings products, real estate and agricultural loans, and other financial services, as well as car and two-wheeler, health and death, personal, borrower leisure and daily life, and home insurance products. the company also provides consumer credit comprising personal, car, and student and apprentice loans; and foreign exchange, real estate investment, cash management, business creation financing, leasing, medium-term credit, and financial investment services, as well as collection and treasury solutions. it serves individuals, private bank, professionals, farmers, businesses, associations, and public community and social housing customers. the company was incorporated in 1995 and is based in poitiers, france. caisse régionale de crédit agricole mutuel de la touraine et du poitou société coopérative operates as a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam touraine cci has a trailing twelve months eps of €14.83.

pe ratio

crcam touraine cci has a trailing twelve months price to earnings ratio of 5.5. meaning, the purchaser of the share is investing €5.5 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.77%.

yearly top and bottom value

crcam touraine cci's stock is valued at €81.52 at 22:30 est, under its 52-week high of €86.50 and way higher than its 52-week low of €54.01.

revenue growth

year-on-year quarterly revenue growth grew by 5.6%, now sitting on 316.25m for the twelve trailing months.

more news about crcam touraine cci.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com